Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting anti-TSLP monoclonal antibody currently in a Phase 2 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific, which has broad therapeutic application across immunological diseases. The company is building a pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Windward Bio launched in January 2025 with a $200M Series A led by top-tier investors.

Windward Bio

Scott Applebaum

This department oversees the planning, execution, and management of clinical trials and regulatory submissions.

Clinical Development

This department provides governance and oversight through the involvement of board members in organizational decision-making.

Board Oversight

This department focuses on overseeing clinical research and data strategies to enhance scientific understanding and innovation.

Clinical Science

This department oversees company compliance with laws and regulations while managing employee relations and organizational culture.

Legal and Human Resources

This department oversees project management and financial planning processes to ensure effective resource allocation and lifecycle management.

Program and Financial Management

This department manages and oversees clinical trials and biosample operations across various regions.

Windward Bio

Org chart

Teams

Clinical Development

Board Oversight

Clinical Science

Legal and Human Resources

Program and Financial Management

Clinical Operations

Offices

Windward Bio

Org chart

Teams

Clinical Development

Board Oversight

Clinical Science

Legal and Human Resources

Program and Financial Management

Clinical Operations

Offices

Related companies